Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

New and Emerging Treatments for Migraine

Rubesh Gooriah and Fayyaz Ahmed*

Migraine can be extremely disabling with a considerable impact on the life of an individual in their ability to work or perform activities of daily living. The arrival of ‘triptans’ in the early 1990s saw a major change in the way migraines were treated, and ‘triptans’ remain the gold standard in treating an acute attack. For a long time there was very little progress in identifying new targets for acute treatment and there was virtually nothing new in migraine prevention. However, in recent times, considerable research has been made in understanding the pathophysiology of migraine and the coming decade should see a drastic change in treating and preventing migraines with potential neuro-pharmacological agents and non invasive neuro-stimulation. This article briefly discusses the pathophysiology of migraine and reviews new therapeutic options as well as some promising treatments undergoing clinical trials.